ST Elevation Myocardial Infarction
Conditions
Brief summary
NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).
Detailed description
After someone has a MI, their heart 'remodels', which means that it changes in size and shape. This damage can lead to it being weaker and less efficient, and ultimately to major heart problems. There are some drugs currently available which help prevent remodelling and are used for treatment post-MI. However, there is still a high rate of remodelling and major heart problems in people post-MI. NP202 works in a different way to the drugs that are currently approved, and has been shown in animal studies to prevent post-MI remodelling. This study will assess NP202 versus placebo on remodelling over a 3 month treatment period, with 1 month follow up
Interventions
DRUGNP202
Active
OTHERPlacebo
Placebo
Sponsors
Armaron Bio Pty Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Have had a confirmed ST elevation myocardial infarction (STEMI) in the previous 5 days, which met all of the following criteria; * ≥ 0.2mV ST elevation in 2 or more V1 - V6 leads with presentation in a maximum of 12 hours of onset of symptoms * Troponin levels \>10 x upper limit of normal (ULN) at the site's local laboratory. * Successful revascularisation by Percutaneous Coronary Intervention (PCI) * Have left ventricular dysfunction post STEMI as evidenced by left ventricular ejection fraction (LVEF) ≤40% confirmed by echocardiogram at screening. * Are receiving guideline-directed medical therapy for acute MI and post-MI left ventricular (LV) dysfunction according to national cardiology society/heart association STEMI guidelines.
Exclusion criteria
* Known cardiomyopathy or heart failure prior to MI. * Cardiogenic shock and/or systolic blood pressure \<85mmHg at Screening. * Clinical history of ejection fraction ≤40% prior to this MI, or multiple prior MIs. * Daily use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or cyclooxygenase-2 (COX-2) inhibitors in the past month. * Presence of device/hardware incompatible with MRI * Estimated glomerular filtration rate (eGFR) \<30ml/min * Liver function tests 3 x ULN due to non-cardiac disease * Have received any investigational research agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy as measured by Change from baseline in left ventricular end systolic volume index (LVESVi) | From baseline to 3 months post MI | Change from baseline in left ventricular end systolic volume index (LVESVi) as assessed by MRI at 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy as measured by Change from baseline in LV end diastolic volume index (LVEDVi) | From baseline to 3 months post MI | Change from baseline in LV end diastolic volume index (LVEDVi) as assessed by MRI at 3 months. |
| Efficacy as measured by Change from baseline in LV ejection fraction (LVEF) | From baseline to 3 months post MI | Change from baseline in LVEF as assessed by MRI at 3 months. |
| Efficacy as measured by Change from baseline in LV diastolic function | From baseline to 3 months post MI | Changes from baseline in LV diastolic function based on LV peak filling rate as assessed by MRI at 3 months. |
| Efficacy as measured by Change from baseline in relative infarct size | From baseline to 3 months post MI | Change from baseline in relative infarct size as a percent of LV mass as assessed by late contrast enhancement MRI at 3 months. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety as assessed by occurrence of adverse events (AE) | From baseline to end of study (4 months) | All AE occurring during the study will be recorded |
| Efficacy as assessed by laboratory biomarkers | At Baseline and Months 1, 2 and 3 | Absolute values and changes from baseline in serum biomarker levels (Troponin I, Troponin T, high sensitivity C reactive protein (hs-CRP) and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) |
| Safety as assessed by changes in laboratory results | At Baseline, Week 2, and Months 1, 2, 3 and 4 | Biochemistry, haematology, prostate specific antigen (PSA), urinalysis |
| Safety as assessed by changes in physical examination | At Baseline, Week 2, and Months 1, 2, 3 and 4 | Changes in physical examination finding including vital signs (heart rate, blood pressure, respiratory rate, temperature) |
| Safety as assessed by changes in 12-lead electrocardiograms (ECGs). | At Baseline, Week 2, and Months 1, 2, 3 and 4 | Changes in ECG intervals |
| Trough levels of NP202 in plasma | At Baseline, Week 2 and at Months 1, 2 and 3 | Concentrations of NP202 in plasma in a subset of 30 subjects. |
Countries
Australia
Contacts
Primary ContactGrant McLachlan
Outcome results
None listed